In a landmark development for oncology, a pioneering clinical trial has revealed that a short, targeted course of immunotherapy administered prior to surgery can essentially "melt away" certain bowel cancers, leading to an unprecedented three-year period without recurrence. The findings from the NEOPRISM-CRC trial, spearheaded by University College London (UCL) and University College London Hospitals (UCLH) NHS Foundation Trust, suggest a fundamental paradigm shift in how we approach the treatment of high-risk colorectal cancers.
The study, which is slated for formal presentation at the American Association for Cancer Research (AACR) Annual Meeting in 2026, challenges the long-standing reliance on aggressive post-operative chemotherapy, offering patients a more durable and less toxic alternative.
The NEOPRISM-CRC Trial: A New Frontier in Oncology
The NEOPRISM-CRC trial focused on a specific, high-risk subset of bowel cancer patients: those with stage two or three disease characterized by a genetic profile known as MMR-deficient (mismatch repair deficient) or MSI-high (microsatellite instability-high). While these patients represent roughly 10–15% of all stage two or three bowel cancer cases—equating to approximately 2,000 to 3,000 individuals annually in the UK—they often face significant challenges with conventional treatment pathways.
Traditionally, the standard of care for these patients has involved surgical intervention followed by three to six months of grueling chemotherapy. However, this approach carries a substantial risk of relapse; historically, about 25% of these patients see their cancer return within three years.
The NEOPRISM-CRC protocol took a radical departure from this norm. Participants were administered the immunotherapy drug pembrolizumab—a checkpoint inhibitor that "unmasks" cancer cells, allowing the immune system to identify and destroy them—for just nine weeks prior to their scheduled surgery. The results have been nothing short of transformative.
Chronology of a Medical Breakthrough
The success of the trial has unfolded in distinct, highly promising phases:
- Initial Enrollment: Researchers recruited 32 patients across five major UK medical centers, including University Hospital Southampton, St. James’s University Hospital in Leeds, and The Christie NHS Foundation Trust in Manchester.
- The Immunotherapy Phase: Patients bypassed standard pre-operative protocols, receiving up to nine weeks of pembrolizumab. The primary goal was to see if the immune system could be primed to attack the tumor before it was surgically removed.
- Surgical Intervention: Following the nine-week course, patients underwent standard bowel cancer surgery.
- The Milestone Results: Early data indicated that 59% of patients showed no detectable signs of disease post-surgery.
- Long-term Follow-up: At the 33-month mark, researchers reported that none of the trial participants had experienced a recurrence of their cancer. Even among those who had microscopic traces of disease remaining after the immunotherapy, the cancer remained dormant and failed to grow or spread during the follow-up period.
Supporting Data: The Power of Personalization
The strength of the NEOPRISM-CRC study lies not just in the clinical outcomes, but in the sophisticated translational research conducted alongside it. By analyzing blood samples and tumor tissue, the team sought to understand the "why" behind the success and how to replicate it for broader populations.
The Role of Circulating Tumor DNA (ctDNA)
A pivotal component of the research involved the development of personalized blood tests to monitor circulating tumor DNA (ctDNA). The team found a near-perfect correlation between the disappearance of tumor DNA from the bloodstream and the absence of residual disease.
Yanrong Jiang, a clinical PhD student at the UCL Cancer Institute and the first author of the latest abstract, noted, "When tumor DNA disappeared from the blood, patients were much more likely to have no cancer remaining, and this matched the long-term results we’re now seeing."
Predictive Immune Profiling
Beyond ctDNA, the researchers utilized immune profiling of tumor tissue taken before the first cycle of treatment. This allows clinicians to identify the "immune signature" of a tumor, potentially predicting which patients will respond best to immunotherapy. This move toward precision medicine ensures that patients receive the most effective therapy while sparing others from treatments that may be ineffective, thereby optimizing healthcare resources and patient quality of life.
Official Responses and Clinical Perspectives
The medical community has greeted these findings with cautious optimism and excitement. Dr. Kai-Keen Shiu, the Chief Investigator of the trial and a Consultant Medical Oncologist at UCLH, emphasized the gravity of these results.
"Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging," Dr. Shiu stated. "It strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers."
Dr. Shiu highlighted the future of the field, noting, "What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling. These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy before and after surgery versus patients at higher risk of disease progression or relapse."
Professor Marnix Jansen, who led the translational research at the UCL Cancer Institute, underscored the biological significance of the trial. "These results not only confirm the durability of responses we saw almost three years ago, but also provide crucial biological insights into why immunotherapy is so effective in this setting."
Patient Testimony: The Human Impact
While the statistical data is compelling, the personal impact of the trial is best illustrated by the story of Christopher Burston, a 73-year-old from Dorset. Diagnosed in February 2023 after a routine bowel screening test indicated blood in his stool, Burston was identified as a candidate for the NEOPRISM-CRC trial.
"The outcome of the surgery was essentially that the cancer had melted away—these were the doctor’s words," Burston recalled. "The immunotherapy had an almost immediate effect."
After receiving three doses of pembrolizumab over nine weeks, Burston underwent surgery in May 2023. He reported few side effects and a smooth recovery. More than three years post-diagnosis, Burston is living an active life, largely untroubled by his past encounter with stage three cancer. His experience reflects the core objective of the trial: not just to extend life, but to preserve the quality of life by avoiding the long-term toxicity associated with traditional chemotherapy.
Implications for the Future of Cancer Care
The implications of the NEOPRISM-CRC trial extend far beyond the specific subset of bowel cancer patients currently being treated.
1. Moving Away from "One Size Fits All"
The success of this trial provides a template for "neoadjuvant" (pre-operative) immunotherapy. If this model can be validated in larger, Phase III trials, it could fundamentally change the standard of care for a wide array of solid tumors. By shrinking tumors or eliminating them entirely before surgery, surgeons may be able to perform less invasive procedures, leading to faster recovery times and better functional outcomes for patients.
2. Reducing Toxicity
Traditional chemotherapy is systemic and often harsh, affecting healthy cells alongside cancerous ones. By utilizing the patient’s own immune system, pembrolizumab offers a targeted approach that is often better tolerated. Reducing the reliance on post-operative chemotherapy could lead to a significant decrease in long-term treatment-related complications.
3. Economic and Healthcare System Benefits
With bowel cancer being the fourth most common cancer in the UK, accounting for 44,000 new cases annually, any treatment that reduces recurrence rates offers a substantial benefit to the National Health Service (NHS). By avoiding costly follow-up treatments for relapsed patients and reducing hospital stays, the NEOPRISM approach could prove to be a more efficient and sustainable model for oncology care.
4. The Rising Challenge of Early-Onset Cancer
The study is particularly timely given the concerning trend of rising bowel cancer rates among adults under 50. As clinicians grapple with how to treat a younger, more active demographic, the ability to provide shorter, highly effective treatments that allow for a quick return to daily life is a critical medical priority.
Conclusion
The NEOPRISM-CRC trial represents a triumph of modern oncology. By combining the precision of genetic profiling with the biological power of immunotherapy, researchers have provided a glimpse into a future where cancer treatment is not just about survival, but about curative, targeted, and personalized interventions.
As the trial continues to track long-term data and researchers work to integrate personalized blood tests into routine clinical practice, the medical community remains hopeful that this breakthrough will soon reach the broader population of patients who need it most. For those like Christopher Burston, the trial has already provided the most valuable gift of all: the ability to focus on the future, rather than the disease.
